

28th November 2014

The ASX Market Announcements Platform
ASX Limited
By E-lodgement

ASX Announcement

RESULTS OF 2014 ANNUAL GENERAL MEETING

Pursuant to ASX listing rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that all resolutions put to the Annual General Meeting of the shareholders today were passed on a show of hands.

The resolutions passed by ordinary resolution were:

1. Adoption of remuneration report
2. Re-election of Director – Brendan De Kauwe
3. Election of Director – Robert Crombie
4. Election of Director – Paul Hopper
5. Issue of options to Robert Crombie
6. Issue of Consideration Shares to related parties and increase in voting power
7. Issue of Consideration Shares to unrelated parties
8. Consolidation of capital

The proxy votes in respect of each resolution were:

Resolution	For	Against	Abstain	Discretionary
1	42,443,415	4,552	25,000,000	20,040,301
2	67,441,967	6,000	-	20,040,301
3	67,441,847	6,120	-	20,040,301
4	67,441,847	6,120	-	20,040,301
6	67,436,965	11,002	-	20,040,301
8	67,436,965	10,552	450	20,040,301
9	67,436,965	10,552	450	20,040,301
10	54,327,399	822,119	450	32,338,300
11	30,144,899	2,620	25,000,000	32,340,299

Resolution 11 was withdrawn as a consequence of the Remuneration Report being approved at both the 2013 Annual General Meeting (held earlier today) and this 2014 Annual General Meeting.

The following resolutions were carried by a sufficient majority as a special resolution:

RESOLUTION 5 – CHANGE OF NAME

To consider and, if thought fit, to pass, the following resolution as a special resolution:

"That, for the purposes of section 157(1)(a) of the Corporations Act and for all other purposes, approval is given for the name of the Company to be changed to "Prescient Therapeutics Limited"."

RESOLUTION 7 – APPROVAL OF 10% PLACEMENT CAPACITY

To consider and, if thought fit, to pass the following resolution as a special resolution:

"That, for the purposes of Listing Rule 7.1A and for all other purposes, approval is given for the issue of Equity Securities totalling up to 10% of the issued capital of the Company at the time of issue, calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions set out in the Explanatory Statement."

The motions were carried as a special resolution by a sufficient majority, the details of which are as follows:

Resolution	For	Against	Abstain	Discretionary
5	67,447,847	120	-	20,040,301
7	67,447,397	120	450	20,040,301

Yours faithfully

Sean Henbury

Company Secretary

For further information contact:

Mr. Rudi Michelson

Monsoon Communications

Ph: +61 (0) 3 9620 3333

Dr. Robert Crombie

Managing Director

Ph: +61 (0) 3 9982 4563

About Virax

Virax is a clinical stage oncology company currently engaged in the development of novel products for the treatment of cancer. It holds an exclusive worldwide license to the novel cancer compound GGTI-2418 for the treatment of multiple myeloma, breast and pancreatic cancer.

GGTI-2418 is expected to enter Phase 1b/2 clinical trials in breast cancer and myeloma in early 2015.

Virax owns the US oncology company AKTivate and its novel TCN-P cancer drug. The company's technology inhibits the highly promising drug target AKT and includes two active clinical trials – a Phase 1b/2 in breast cancer and an active Phase 1b in ovarian cancer. These trials are funded by US government authorities, including grants from the Department of Defence and National Cancer Institute.

In addition, the company has granted a license to major French biotechnology company Transgene for access to its Co-X-Gene™ technology for use in two of Transgene's immunotherapeutic products.